We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Non-small Cell Lung Cancer as a Chronic Disease -- A Prospective Study from the Czech TULUNG Registry.
- Authors
BRATOVA, MONIKA; KARLINOVA, BARA; SKRICKOVA, JANA; PESEK, MILOS; KOLEK, VITEZSLAV; KOUBKOVA, LEONA; HRNCIARIK, MICHAL; KREJCI, JANA; BARINOVA, MAGDA; HAVEL, LIBOR; GRYGARKOVA, IVONA; BRAT, KRISTIAN
- Abstract
Aim: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively. Patients and Methods: Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression-free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival. Results: Survival at 2 years was more frequent in cohort 2015-16 compared to cohort 2011-12 (43.2% vs. 24% for adenocarcinoma; p<0.001 and 28.7% vs. 11.8% for squamous-cell lung carcinoma; p=0.002). Assignment to cohort 2015-16 and treatment multilinearity (two or more lines in sequence) were associated with higher probability of 2-year survival (hazard ratio=0.666 and hazard ratio=0.597; p<0.001). Comparison of 2-year survivors from both cohorts showed no differences. Conclusion: Survival at 2 years probability in stage IIIB-IV NSCLC doubled between 2011-12 and 2015-16; advanced-stage NSCLC may be considered a chronic disease in a large proportion of patients.
- Subjects
NON-small-cell lung carcinoma; CHRONIC diseases; PROTEIN-tyrosine kinases; ADENOCARCINOMA; ANAPLASTIC lymphoma kinase
- Publication
In Vivo, 2020, Vol 34, Issue 1, p369
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.11783